Literature DB >> 16264901

Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?

John Goldman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16264901     DOI： 10.1038/ncponc0110

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN： 1743-4254


× No keyword cloud information.
  4 in total

1.  Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.

Authors:  Elia Mattarucchi; Orietta Spinelli; Alessandro Rambaldi; Francesco Pasquali; Francesco Lo Curto; Leonardo Campiotti; Giovanni Porta
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

2.  Role of NCCN in Integrating Cancer Clinical Practice Guidelines into the Healthcare Debate.

Authors:  Al B Benson; Elizabeth Brown
Journal:  Am Health Drug Benefits       Date:  2008-02

3.  Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.

Authors:  Theodore Darkow; Henry J Henk; Simu K Thomas; Weiwei Feng; Jean-Francois Baladi; George A Goldberg; Alan Hatfield; Jorge Cortes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Reducing uncertainty in health-care resource allocation.

Authors:  T Simonsson; K Sjölund; P Bümming; H Ahlman; B Nilsson; A Odén
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.